Table 3.
Demographic and clinical characteristics of placebo responders and non-responders.
| Non-responder (n = 45) | Responder (n = 43) | p | |
|---|---|---|---|
| Venoplasty, n | 24 | 18 | 0.19 |
| Sham, n | 21 | 25 | |
| Males, n | 18 | 13 | 0.24 |
| Females, n | 27 | 30 | |
| Age, mean (SD) | 55.0 (7.4) | 53.0 (8.5) | 0.26 |
| Disease duration, mean (SD) | 18.8 (9.6) | 16.7 (8.1) | 0.29 |
| MS type (n) | |||
| RRMS | 25 | 30 | 0.35 |
| PPMS | 6 | 3 | |
| SPMS | 14 | 10 | |
| Baseline EDSS, median (range) | 4.0 (0–6.5) | 4.0 (0–6.5) | 0.09 |
| Baseline MSFC, mean (SD) | 7.2 (6.2) | 8.9 (4.9) | 0.17 |
| 25 foot walk, mean (SD) | 15.80 (12.15) | 11.87 (7.24) | 0.07 |
| 9 hole peg test, mean (SD) | 108.50 (49.73) | 94.41 (36.04) | 0.13 |
| PASAT, mean (SD) | 37.53 (14.70) | 38.63 (14.97) | 0.73 |
| Baseline MSQOL-54 PH | 55.54 (21.57) | 56.96 (18.79) | 0.74 |
RRMS = Remitting relapsing MS; PPMS = primary progressive MS; SPMS = secondary progressive MS; EDSS = expanded disability status scale; MSFC = multiple sclerosis functional composite; PASAT = paced auditory serial addition test; MSQOL-54 PH = multiple sclerosis quality of life-54, physical health composite. For MSFC, raw scores rather than z-scores are given.